Genetic Engineering & Biotechnology News

APR15 2017

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link: http://gen.epubxp.com/i/806913

Contents of this Issue

Navigation

Page 23 of 37

22 | APRIL 15, 2017 | GENengnews.com | Genetic Engineering & Biotechnology News GEN What does modular automation mean to Thermo Fisher? Mr. Tillich The ability to use modular auto- mation increases the usage rate of the process equipment and cleanroom space. Utilization is one of the key elements to reduce the cost of goods and increase competitiveness. GEN What are the main benefits of using modular automation technology for the laboratory production line? Mr. Tillich In a complex matrix of competitors, including those focusing on originators and biosimilars, or when you think about the vac- cine market, with sporadic market demands, it becomes a strategic decision to be prepared for rapid changes in R&D or production. Process formats and volumes are varying, sometimes un- predictable. Additional or fewer process steps, higher or lower volumes need to be handled, in a GMP-compliant manner. As the down time and modification cost need to be low, modular automation is the right answer because it can provide the flexibility required for those varying circumstances. GEN Can you give one or two examples of Thermo Fisher's hardware and software in the biomanufacturing arena that illustrates this concept of modular automation and how this improves the bioproduction process? Mr. Tillich The acquisition of Finesse al- lows Thermo Fisher to extend the supply of best-in-class bioprocessing vessels, such as the new HyPerforma 2000 L Single-Use Bioreactor with a turn-down-ratio of 5:1 or the 5000 L imPULSE Single-Use Mix- ers, by a highly configurable, scalable, Thermo Fisher Scientific Adopts a Modular Automation Path Bioprocessing Perspectives You can count on Mary Ann Liebert for your publishing needs. Mary Ann welcomes your comments at: ceo@liebertpub.com Contact us at (914) 740-2100 or visit our website for more information www.liebertpub.com There is a Mary Ann Liebert at Mary Ann Liebert, Inc. and that makes a difference! For Mary Ann Liebert, publishing is not just a profession, it is a passion. As the founder, president, and CEO of one of the most respected privately-held STM publishing houses, her impact on scholarly communications is profound. Mary Ann Liebert... • takes a personal interest in each journal published • insists on quality, value, and credibility of content • believes in investing in products for the long term • launches journals on critical topics and emerging fields • champions improved access to scholarly communication • provides unique author services to ensure article discoverability • supports flexible models for authors, libraries, and institutions Platform Approach Integrates Multiple Technologies for a Variety of Applications Insights Horizon Discovery Group entered into a research and development collaboration and license agreement with Amplycell to evaluate the impact of Amplycell's BOOST cell-line optimization technology on Hori- zon's parental GS (glutamine synthetase) null CHO-K1 cell line. Amplycell's Cell Fitness Technologies, which include BOOST, consist of a four- stage process to optimize cell lines in terms of stability and productivity. Cell lines can be stimulated using AmplyCell's Cell Fitness Technologies at any stage of Horizon Discovery and Amplycell Ink Deal for Bioproduction Cell-Line Optimization Horizon is evaluating the impact of Amplycell's technology on the expression capability of Horizon's parental GS-null CHO-K1 cell line. Horizon Discovery At the recent Interphex Conference in New York City, Thermo Fisher Scientific officials pointed out that it is increasingly focusing on modular automation technologies to assist companies in their drug discovery, R&D, and biomanufacturing activities. GEN interviewed Dirk Tillich, vice president, global sales, Finesse, a part of Thermo Fisher Scientific, to find out more about Thermo Fisher's strategy for relying on modular automation.

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - APR15 2017